Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan Sells 2,771 Shares

Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan sold 2,771 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $28,070.23. Following the completion of the transaction, the chief executive officer now directly owns 526,702 shares in the company, valued at approximately $5,335,491.26. This represents a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Enfusion Stock Down 3.1 %

ENFN traded down $0.32 on Friday, hitting $9.97. The company had a trading volume of 351,403 shares, compared to its average volume of 388,016. The business’s fifty day simple moving average is $10.09 and its 200 day simple moving average is $9.18. Enfusion, Inc. has a 12-month low of $7.52 and a 12-month high of $11.38. The company has a market cap of $1.28 billion, a PE ratio of 249.31, a PEG ratio of 3.98 and a beta of 0.95.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Piper Sandler boosted their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research note on Monday, December 23rd. Stifel Nicolaus lifted their price objective on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.25.

Hedge Funds Weigh In On Enfusion

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its holdings in Enfusion by 29.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 159,555 shares of the company’s stock valued at $1,359,000 after buying an additional 36,257 shares during the period. Principal Financial Group Inc. increased its position in Enfusion by 15.6% during the second quarter. Principal Financial Group Inc. now owns 56,524 shares of the company’s stock valued at $482,000 after acquiring an additional 7,611 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Enfusion by 30.3% in the second quarter. Rhumbline Advisers now owns 59,435 shares of the company’s stock valued at $506,000 after acquiring an additional 13,832 shares during the period. Victory Capital Management Inc. bought a new stake in shares of Enfusion in the 2nd quarter worth about $183,000. Finally, Arizona State Retirement System purchased a new position in shares of Enfusion during the 2nd quarter worth about $86,000. Hedge funds and other institutional investors own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.